ViiV’s New HIV Drug “Trii” Has Officially Been FDA-Approved
Triumeq is a tablet that must be taken daily. Each tablet contains 50 mg dolutegravir, 600 mg abacavir, and 300 mg lamivudine. The correct dose is one pill taken once daily, either with or without food.
FDA approval is based on data from two clinical trials: In one trial involving people starting ARV therapy for the first time, the regimen was found to be superior to Atripla. Another study confirmed that taking Triumeq results in blood levels of the ARVs equivalent to all 3 drugs taken together as separate tablets.
It is not recommended for people with known HIV resistance to abacavir, lamivudine, or any of the approved intergrase inhibitors.
Click here for a complete guide to the latest fixed-dose, once-daily combination tablet, Triumeq.

ViiV’s New HIV Drug “Trii” Has Officially Been FDA-Approved

  • Triumeq is a tablet that must be taken daily. Each tablet contains 50 mg dolutegravir, 600 mg abacavir, and 300 mg lamivudine. The correct dose is one pill taken once daily, either with or without food.
  • FDA approval is based on data from two clinical trials: In one trial involving people starting ARV therapy for the first time, the regimen was found to be superior to Atripla. Another study confirmed that taking Triumeq results in blood levels of the ARVs equivalent to all 3 drugs taken together as separate tablets.
  • It is not recommended for people with known HIV resistance to abacavir, lamivudine, or any of the approved intergrase inhibitors.


Click here for a complete guide to the latest fixed-dose, once-daily combination tablet, Triumeq.

HIV Treatment Demand in Poorer Nations Will Keep RisingBy the end of 2016, the demand for ARVs in low and middle-income countries is estimated to rise from 11.5 to 16.8 million people. This study asks: Which HIV treatment combos will be used the most?

HIV Treatment Demand in Poorer Nations Will Keep Rising

By the end of 2016, the demand for ARVs in low and middle-income countries is estimated to rise from 11.5 to 16.8 million people. This study asks: Which HIV treatment combos will be used the most?

Providing TaSP When Stuck Between a Rock & a Hard Place

In the absence of universal antiretroviral (ARV) treatment, should we prioritize on providing HIV meds to the main drivers of the epidemic first before making them available to the rest of the population? This new theory from aidsmap says yes.

If countries followed the idea, it would mean injection drug users and female sex workers would be treated before all other at-risk groups.

One More Study Shows PrEP Doesn’t Lead to Riskier SexPrEP was approved in 2012 as an HIV prevention tool that can reduce the risk of transmission by more than 90% if used correctly. However, the antiretroviral has remained controversial, and sparsely used, in no small part because of concerns that it will lead to sexual risk bingeing.

One More Study Shows PrEP Doesn’t Lead to Riskier Sex

PrEP was approved in 2012 as an HIV prevention tool that can reduce the risk of transmission by more than 90% if used correctly. However, the antiretroviral has remained controversial, and sparsely used, in no small part because of concerns that it will lead to sexual risk bingeing.

'Quad' Is As Effective As Older ARV Options, With Fewer Side EffectsThe once-daily combination therapy Stribild,aka: the “Quad” because it contains 4 anitretrovirals, is just as effective as both Atripla therapy & a Reyataz plus Truvada combination. Plus, Stribild is far less likely to give you those crazy dreams, among other psychiatric side effects.For more info, click here.

'Quad' Is As Effective As Older ARV Options, With Fewer Side Effects

The once-daily combination therapy Stribild,aka: the “Quad” because it contains 4 anitretrovirals, is just as effective as both Atripla therapy & a Reyataz plus Truvada combination. Plus, Stribild is far less likely to give you those crazy dreams, among other psychiatric side effects.

For more info, click here.

New HIV Care Guidelines Now that antivirals have succeeded in giving a normal life span to many people with HIV, IDSA has urged clinicians to focus their energies outside of the virus and back to primary care.

“In many HIV practices now, 80% of patients with HIV infection have the virus under control. This means that primary care physicians need a better grasp of the impact HIV care has on routine health care. Doctors need to tell their HIV-infected patients, Your HIV disease is controlled, and we need to think about the rest of you.”—Judith A. Aberg, MD, lead author of the new guidelines.

New HIV Care Guidelines

Now that antivirals have succeeded in giving a normal life span to many people with HIV, IDSA has urged clinicians to focus their energies outside of the virus and back to primary care.

“In many HIV practices now, 80% of patients with HIV infection have the virus under control. This means that primary care physicians need a better grasp of the impact HIV care has on routine health care. Doctors need to tell their HIV-infected patients, Your HIV disease is controlled, and we need to think about the rest of you.

—Judith A. Aberg, MD, lead author of the new guidelines.